Omicron-targeted vaccines do no better than original jabs in early tests

Waltz, Emily

3 min read Original article ↗
  • NEWS

Experiments in animals show that boosters customized for the fast-spreading COVID variant offer little advantage over standard jabs.

By

  1. Emily Waltz

As the Omicron variant of SARS-CoV-2 continues its global rampage, vaccine makers are pouring resources into clinical trials of COVID-19 shots tailored to the highly transmissible variant. But a raft of early animal studies suggest that Omicron-specific boosters offer no advantage over a third dose of current vaccines1–4.

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

27,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 52 print issues and online access

199,00 € per year

only 3,83 € per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-022-00003-y

References

  1. Gagne, M. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?s=08 (2022).

  2. Ying, B. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.02.07.479419v1 (2022).

  3. Lee, I.-J. et al. Preprint at bioRixv https://www.biorxiv.org/content/10.1101/2022.01.31.478406v1 (2022).

  4. Hawman, D. W. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.01.31.478520v1 (2022).

Download references

Subjects

Latest on:

Nature Careers

Jobs